aminoglutethimide has been researched along with Hormone-Dependent Neoplasms in 52 studies
Aminoglutethimide: An aromatase inhibitor that is used in the treatment of advanced BREAST CANCER.
aminoglutethimide : A dicarboximide that is a six-membered cyclic compound having ethyl and 4-aminophenyl substituents at the 3-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aminoglutethimide is an effective treatment for advanced postmenopausal breast cancer, acting in a novel way." | 8.77 | Aminoglutethimide--a new endocrine therapy in breast cancer. A cancer research review. ( Harris, AL, 1985) |
| "44 postmenopausal women with progressive soft tissue, osseous and/or pleuropulmonal metastases of breast cancer were treated with aminoglutethimide (Rodazol) and hydrocortisone." | 7.68 | [Results of hormone therapy with aminoglutethimide (Rodazol) in postmenopausal metastatic breast cancer]. ( Brockmann, B; Geschke, E; Schmidt, UM, 1991) |
| "About one third of unselected postmenopausal women with advanced breast cancer respond to treatment with aminoglutethimide and hydrocortisone, but they all eventually relapse, and further progression of disease occurs." | 7.67 | Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy. ( Dowsett, M; Harris, AL; Jeffcoate, SL; Smith, IE, 1984) |
| "Thirty-four postmenopausal patients with advanced breast cancer had an overall objective response rate of 47% when treated with aminoglutethimide and hydrocortisone initially and a response rate of 24% when crossed over to therapy with tamoxifen after progression on aminoglutethimide." | 7.66 | Cross-over comparison of tamoxifen and aminoglutethimide in advanced breast cancer. ( Boucher, AE; Dixon, RJ; Harvey, HA; Lipton, A; Santen, RJ; Shafik, AS; White, DS, 1982) |
| "Aminoglutethimide (AG) is an effective chemical ablative form of therapy for metastatic breast cancer in postmenopausal women." | 7.66 | Influence of estrogen receptor status on response of metastatic breast cancer to aminoglutethimide therapy. ( Cox, CE; Harvey, HA; Lawrence, BV; Lipton, A; Santen, RJ; Smart, EK; Wells, SA; White, DS, 1980) |
| "Human breast neoplasms can be divided into hormone-dependent and hormone-independent subtypes." | 5.26 | Adequacy of estrogen suppression with aminoglutethimide and hydrocortisone as treatment of human breast cancer: correlation of hormonal data with clinical responses. ( Boucher, AE; Harvey, H; Lipton, A; Samojlik, E; Santen, RJ; Worgul, TJ, 1982) |
| "Randomized clinical trials have established the role of third-generation aromatase inhibitors (AIs) (letrozole, anastrozole, and exemestane) as standard treatment for patients with hormone-sensitive metastatic breast cancer who have experienced disease progression with antiestrogen therapy." | 4.82 | A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer. ( Rose, C, 2003) |
| "The new generation of selective aromatase inhibitors (anastrozole, letrozole and exemestane) offer a significant efficacy and safety advantage over both older agents in this class (aminoglutethimide) and the progestins (megestrol acetate (MA)), as second-line treatment for postmenopausal women with advanced hormone-dependent breast cancer who have failed on tamoxifen therapy." | 4.81 | A summary of second-line randomized studies of aromatase inhibitors. ( Buzdar, AU, 2001) |
| " Among the steroid substrate analogs, 4-hydroxyandrostenedione has been shown to be effective in breast cancer patients with advanced disease and was recently approved for treatment in the United Kingdom." | 4.78 | Aromatase, its inhibitors and their use in breast cancer treatment. ( Brodie, AM, 1993) |
| "Aminoglutethimide is an effective treatment for advanced postmenopausal breast cancer, acting in a novel way." | 4.77 | Aminoglutethimide--a new endocrine therapy in breast cancer. A cancer research review. ( Harris, AL, 1985) |
| "We evaluated the comparative effects of aminoglutethimide (AG) on androgen and estrogen levels estrone ([E1], estradiol [E2], plasma dehydroepiandrosterone-sulfate [DHEA-S], testosterone [T], dihydrotestosterone [DHT], delta 4-androstenedione [delta 4-A]), follicle-stimulating hormone (FSH), luteinizing hormone (LH), and prolactin in postmenopausal patients with breast cancer randomly allocated to either AG treatment or bilateral surgical adrenalectomy as a control group." | 4.76 | Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma. ( Samojlik, E; Santen, RJ; Veldhuis, JD; Wells, SA, 1980) |
| "Eleven postmenopausal patients with advanced breast cancer were assessed for their response and endocrine changes to low-dose aminoglutethimide (250 mg twice a day) therapy without steroid administration." | 3.68 | Low-dose aminoglutethimide therapy without glucocorticoid administration. Clinical and hormonal findings. ( Kahán, Z; Tóth, I; Vecsernyés, M, 1992) |
| "44 postmenopausal women with progressive soft tissue, osseous and/or pleuropulmonal metastases of breast cancer were treated with aminoglutethimide (Rodazol) and hydrocortisone." | 3.68 | [Results of hormone therapy with aminoglutethimide (Rodazol) in postmenopausal metastatic breast cancer]. ( Brockmann, B; Geschke, E; Schmidt, UM, 1991) |
| "About one third of unselected postmenopausal women with advanced breast cancer respond to treatment with aminoglutethimide and hydrocortisone, but they all eventually relapse, and further progression of disease occurs." | 3.67 | Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy. ( Dowsett, M; Harris, AL; Jeffcoate, SL; Smith, IE, 1984) |
| "Thirty-four postmenopausal patients with advanced breast cancer had an overall objective response rate of 47% when treated with aminoglutethimide and hydrocortisone initially and a response rate of 24% when crossed over to therapy with tamoxifen after progression on aminoglutethimide." | 3.66 | Cross-over comparison of tamoxifen and aminoglutethimide in advanced breast cancer. ( Boucher, AE; Dixon, RJ; Harvey, HA; Lipton, A; Santen, RJ; Shafik, AS; White, DS, 1982) |
| "Aminoglutethimide (AG) is an effective chemical ablative form of therapy for metastatic breast cancer in postmenopausal women." | 3.66 | Influence of estrogen receptor status on response of metastatic breast cancer to aminoglutethimide therapy. ( Cox, CE; Harvey, HA; Lawrence, BV; Lipton, A; Santen, RJ; Smart, EK; Wells, SA; White, DS, 1980) |
| "In conclusion, in a group of metastatic breast cancer patients, treated routinely by systemic therapies it was found, that the use of higher cut-off point for EGF-R positivity can improve the prediction of endocrine sensitivity." | 2.69 | Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction. ( Branković-Magić, MV; Mitrovic, LB; Nesković-Konstantinović, ZB; Nikolić-Vukosavljević, DB; Spuzić, I, 2000) |
| " Patients were then treated with aminoglutethimide according to one of two dosage regimens: (a) aminoglutethimide 1000 mg/day + hydrocortisone 20 mg/day, and (b) aminoglutethimide 250 mg/day." | 2.66 | Correlation of breast tumour aromatase activity and response to aromatase inhibition with aminoglutethimide. ( Bezwoda, WR; Dansey, R; Mansoor, N, 1987) |
| "Thus, management of metastatic breast cancer has largely shifted from surgeons to medical oncologists." | 2.40 | Use of aromatase inhibitors in postmenopausal women with advanced breast cancer. ( Buzdar, AU; Roseman, BJ; Singletary, SE, 1997) |
| "Aminoglutethimide is an inhibitor of adrenal steroid biosynthesis and blocks the conversion of cholesterol to pregnenolone, and therefore reduces levels of adrenal androgens, which are a source of estrogens in both premenopausal and postmenopausal women." | 2.40 | [Aromatase inhibitors--new possibilities in treatment of breast carcinoma]. ( Friedrichs, K; Jänicke, F, 1998) |
| "Aminoglutethimide was the first widely used aromatase inhibitor but had several clinical drawbacks." | 2.40 | Use of aromatase inhibitors in breast carcinoma. ( Harvey, HA; Santen, RJ, 1999) |
| "Research using cell-lines of human breast cancer also suggests that anti-progestins and agents capable of antagonizing steroid-induced growth factors will inhibit tumour growth." | 2.37 | Fundamental research leading to improved endocrine therapy for breast cancer. ( Miller, WR, 1987) |
| "One-third of the cases of breast cancer in postmenopausal women are hormone-dependent and the lesions regress upon treatment with antiestrogens or inhibition of estrogen biosynthesis." | 2.37 | Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulfatase pathways. ( Feil, PD; Leszczynski, D; Manni, A; Santen, RJ; Santner, SJ; Tilson-Mallet, N; Wright, C, 1986) |
| " These findings led to development of a practical regimen of escalating aminoglutethimide dosage in combination with hydrocortisone for treatment of patients with breast carcinoma." | 1.26 | In vivo and in vitro pharmacological studies of aminoglutethimide as an aromatase inhibitor. ( Rosen, HR; Samojlik, E; Santen, RJ; Santner, SJ; Tilsen-Mallett, N; Veldhuis, JD, 1982) |
| "Human breast neoplasms can be divided into hormone-dependent and hormone-independent subtypes." | 1.26 | Adequacy of estrogen suppression with aminoglutethimide and hydrocortisone as treatment of human breast cancer: correlation of hormonal data with clinical responses. ( Boucher, AE; Harvey, H; Lipton, A; Samojlik, E; Santen, RJ; Worgul, TJ, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 26 (50.00) | 18.7374 |
| 1990's | 19 (36.54) | 18.2507 |
| 2000's | 7 (13.46) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hill, J | 1 |
| Moore, H | 1 |
| Vogel, CL | 1 |
| Rose, C | 1 |
| Vicent, MJ | 1 |
| Greco, F | 1 |
| Nicholson, RI | 2 |
| Paul, A | 1 |
| Griffiths, PC | 1 |
| Duncan, R | 1 |
| Mauri, D | 1 |
| Pavlidis, N | 1 |
| Polyzos, NP | 1 |
| Ioannidis, JP | 1 |
| Bruning, PF | 1 |
| Bonfrer, JM | 1 |
| De Jong-Bakker, M | 1 |
| Nooyen, W | 1 |
| Kvinnsland, S | 1 |
| Lønning, PE | 1 |
| Dahl, O | 1 |
| Harvey, HA | 5 |
| Lipton, A | 4 |
| White, DS | 2 |
| Santen, RJ | 9 |
| Boucher, AE | 2 |
| Shafik, AS | 1 |
| Dixon, RJ | 1 |
| Dowsett, M | 3 |
| Harris, AL | 3 |
| Smith, IE | 2 |
| Jeffcoate, SL | 1 |
| Samojlik, E | 3 |
| Veldhuis, JD | 2 |
| Wells, SA | 2 |
| Santner, SJ | 2 |
| Tilsen-Mallett, N | 1 |
| Rosen, HR | 1 |
| Worgul, TJ | 1 |
| Harvey, H | 1 |
| Sterns, EE | 1 |
| Bird, CE | 1 |
| Mackie, KW | 1 |
| Lawrence, BV | 1 |
| Cox, CE | 1 |
| Smart, EK | 1 |
| Brodie, AM | 2 |
| Pronzato, P | 1 |
| Rubagotti, A | 1 |
| Amoroso, D | 1 |
| Bertelli, G | 1 |
| Queirolo, P | 1 |
| Sertoli, MR | 1 |
| Rosso, M | 1 |
| Gallotti, P | 1 |
| Monzeglio, C | 1 |
| Rosso, R | 1 |
| Stein, M | 1 |
| Hultborn, R | 1 |
| Johansson-Terje, I | 1 |
| Bergh, J | 1 |
| Glas, U | 1 |
| Hallsten, L | 1 |
| Hatschek, T | 1 |
| Holmberg, E | 1 |
| Ideström, K | 1 |
| Norberg, B | 1 |
| Ranstam, J | 1 |
| Söderberg, M | 1 |
| Wallgren, UB | 1 |
| Roseman, BJ | 1 |
| Buzdar, AU | 2 |
| Singletary, SE | 1 |
| Cameron, DA | 1 |
| Anderson, ED | 1 |
| Levack, P | 1 |
| Hawkins, RA | 1 |
| Anderson, TJ | 1 |
| Leonard, RC | 1 |
| Forrest, AP | 1 |
| Chetty, U | 1 |
| Bare, RL | 1 |
| Torti, FM | 1 |
| Friedrichs, K | 1 |
| Jänicke, F | 1 |
| Ragaz, J | 1 |
| Nesković-Konstantinović, ZB | 1 |
| Nikolić-Vukosavljević, DB | 1 |
| Branković-Magić, MV | 1 |
| Mitrovic, LB | 1 |
| Spuzić, I | 1 |
| Kardinal, CG | 1 |
| Donegan, WL | 1 |
| Kahán, Z | 1 |
| Tóth, I | 1 |
| Vecsernyés, M | 1 |
| Schmidt, UM | 1 |
| Brockmann, B | 1 |
| Geschke, E | 1 |
| Clavel, M | 1 |
| Fukuoka, M | 1 |
| Kitawaki, J | 1 |
| Yamamoto, T | 1 |
| Okada, H | 1 |
| Garcia Giralt, E | 1 |
| Omodei Zorini, C | 1 |
| von Matthiessen, H | 1 |
| Distler, W | 1 |
| Miller, WR | 2 |
| Fukutomi, T | 1 |
| Knönagel, H | 1 |
| Hauri, D | 1 |
| Wander, HE | 1 |
| Teichmann, AT | 1 |
| Cremer, P | 1 |
| Wieland, H | 1 |
| Kruse, B | 1 |
| Nagel, GA | 1 |
| Kuhn, W | 1 |
| Seidel, D | 1 |
| Paridaens, RJ | 1 |
| Arrigo, C | 1 |
| Heuson, JC | 1 |
| Leszczynski, D | 1 |
| Tilson-Mallet, N | 1 |
| Feil, PD | 1 |
| Wright, C | 1 |
| Manni, A | 1 |
| Walker, KJ | 1 |
| Davies, P | 1 |
| Gorgone, S | 1 |
| Lorenzini, C | 1 |
| Palmeri, R | 1 |
| Belnome, N | 1 |
| Calbo, L | 1 |
| Dattola, P | 1 |
| Melita, P | 1 |
| Bezwoda, WR | 1 |
| Mansoor, N | 1 |
| Dansey, R | 1 |
| Wing, LY | 1 |
| Goss, P | 1 |
| Coombes, RC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Stereotactic Body Radiotherapy (SBRT) for the Treatment of OligoMetastasis in Breast Cancer Patients (STOMP): A Prospective Feasibility Trial[NCT03295916] | Early Phase 1 | 30 participants (Anticipated) | Interventional | 2018-01-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
24 reviews available for aminoglutethimide and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Aromatase inhibitors in breast cancer: current and evolving roles.
Topics: Aminoglutethimide; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasm | 2002 |
Update on the current use of hormonals as therapy in advanced breast cancer.
Topics: Aminoglutethimide; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical | 2003 |
A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast | 2003 |
Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
Topics: Adult; Aged; Aminoglutethimide; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aroma | 2006 |
Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma.
Topics: Adrenalectomy; Aged; Aminoglutethimide; Androgens; Breast Neoplasms; Castration; Estrogens; Female; | 1980 |
Aromatase, its inhibitors and their use in breast cancer treatment.
Topics: Aminoglutethimide; Androstenedione; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast N | 1993 |
Use of aromatase inhibitors in postmenopausal women with advanced breast cancer.
Topics: Aminoglutethimide; Anastrozole; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormo | 1997 |
Emerging role of aromatase inhibitors in the treatment of breast cancer.
Topics: Aged; Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 1998 |
Endocrine therapy of prostate cancer.
Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Aminoglutethimide; Androgen Antagonists; Antineoplasti | 1998 |
[Aromatase inhibitors--new possibilities in treatment of breast carcinoma].
Topics: Aminoglutethimide; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 1998 |
Theoretical considerations for the ideal aromatase inhibitor.
Topics: Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neopla | 1998 |
Aromatase inhibitors: a dose-response effect?
Topics: Aminoglutethimide; Anastrozole; Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplas | 1999 |
Status of aromatase inhibitors in relation to other breast cancer treatment modalities.
Topics: Aminoglutethimide; Anticarcinogenic Agents; Antineoplastic Agents; Aromatase Inhibitors; Breast Neop | 1999 |
Use of aromatase inhibitors in breast carcinoma.
Topics: Adult; Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents, Hormo | 1999 |
A summary of second-line randomized studies of aromatase inhibitors.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Drug Toleran | 2001 |
Cancer of the breast. Endocrine and hormonal therapy.
Topics: Adrenal Cortex Hormones; Adrenalectomy; Adult; Aged; Aminoglutethimide; Antineoplastic Agents; Breas | 1979 |
Management of breast cancer with bone metastases.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; | 1991 |
[Hormonal treatment of breast tumor].
Topics: Adrenalectomy; Aminoglutethimide; Antineoplastic Agents; Breast Neoplasms; Drug Administration Sched | 1990 |
Aromatase inhibitors in the treatment of advanced breast cancer.
Topics: Aminoglutethimide; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Fadrozole; Female; Human | 1989 |
Fundamental research leading to improved endocrine therapy for breast cancer.
Topics: Adrenal Cortex Hormones; Aminoglutethimide; Antineoplastic Agents; Breast Neoplasms; Combined Modali | 1987 |
Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulfatase pathways.
Topics: 17-Hydroxysteroid Dehydrogenases; Adrenalectomy; Aminoglutethimide; Androstenedione; Animals; Aromat | 1986 |
Hormone agonists and antagonists in the treatment of hormone sensitive breast and prostate cancer.
Topics: Aminoglutethimide; Androgen Antagonists; Breast Neoplasms; Estrogen Antagonists; Female; Gonadotropi | 1986 |
Aminoglutethimide--a new endocrine therapy in breast cancer. A cancer research review.
Topics: Adrenal Glands; Aminoglutethimide; Aromatase Inhibitors; Breast Neoplasms; Estrogens; Female; Humans | 1985 |
Could aminoglutethimide replace adrenalectomy?
Topics: Adrenal Cortex; Adrenalectomy; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Clinical Trials | 1985 |
6 trials available for aminoglutethimide and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Second-line hormonotherapy for breast cancer. Uselessness of first-line continuation.
Topics: Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; H | 1993 |
Second-line endocrine treatment of advanced breast cancer--a randomized cross-over study of medroxy-progesterone acetate and aminoglutethimide.
Topics: Aminoglutethimide; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cross-Over Studies; Humans; Me | 1996 |
Primary systemic therapy for operable breast cancer--10-year survival data after chemotherapy and hormone therapy.
Topics: Adult; Aged; Aminoglutethimide; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Axi | 1997 |
Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction.
Topics: Adult; Aminoglutethimide; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Prot | 2000 |
Correlation of breast tumour aromatase activity and response to aromatase inhibition with aminoglutethimide.
Topics: Aminoglutethimide; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Drug Evaluation; Estrogens; Fe | 1987 |
Could aminoglutethimide replace adrenalectomy?
Topics: Adrenal Cortex; Adrenalectomy; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Clinical Trials | 1985 |
23 other studies available for aminoglutethimide and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Polymer therapeutics designed for a combination therapy of hormone-dependent cancer.
Topics: Aminoglutethimide; Antibiotics, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Dru | 2005 |
Influence of ACTH on aminoglutethimide induced reduction of plasma steroids in postmenopausal breast cancer.
Topics: Adrenocorticotropic Hormone; Aminoglutethimide; Breast Neoplasms; Cosyntropin; Drug Therapy, Combina | 1984 |
Treatment of breast carcinoma with aminoglutethimide.
Topics: Aminoglutethimide; Breast Neoplasms; Cortisone; Dexamethasone; Drug Resistance; Drug Therapy, Combin | 1984 |
Aminoglutethimide.
Topics: Aged; Aminoglutethimide; Breast Neoplasms; Female; Humans; Menopause; Middle Aged; Neoplasms, Hormon | 1981 |
Cross-over comparison of tamoxifen and aminoglutethimide in advanced breast cancer.
Topics: Aminoglutethimide; Breast Neoplasms; Female; Humans; Hydrocortisone; Menopause; Middle Aged; Neoplas | 1982 |
Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy.
Topics: Aminoglutethimide; Androstenedione; Breast Neoplasms; Dehydroepiandrosterone; Estradiol; Estrone; Fe | 1984 |
Introduction to the conference, Aromatase: New Perspectives for Breast Cancer.
Topics: Aminoglutethimide; Animals; Aromatase Inhibitors; Breast Neoplasms; Estrogen Antagonists; Estrogens; | 1982 |
In vivo and in vitro pharmacological studies of aminoglutethimide as an aromatase inhibitor.
Topics: Adrenal Cortex; Aminoglutethimide; Aromatase Inhibitors; Breast Neoplasms; Dexamethasone; Drug Admin | 1982 |
Adequacy of estrogen suppression with aminoglutethimide and hydrocortisone as treatment of human breast cancer: correlation of hormonal data with clinical responses.
Topics: Adrenalectomy; Aminoglutethimide; Androgens; Aromatase Inhibitors; Breast Neoplasms; Carcinoembryoni | 1982 |
Is aminoglutethimide an alternative to adrenalectomy for metastatic carcinoma of the breast?
Topics: Adrenalectomy; Adult; Aged; Aminoglutethimide; Breast Neoplasms; Drug Therapy, Combination; Female; | 1982 |
Influence of estrogen receptor status on response of metastatic breast cancer to aminoglutethimide therapy.
Topics: Aminoglutethimide; Breast Neoplasms; Female; Humans; Menopause; Middle Aged; Neoplasms, Hormone-Depe | 1980 |
[Aromatase inhibitor].
Topics: Aminoglutethimide; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Estrogens; Female; | 1993 |
Low-dose aminoglutethimide therapy without glucocorticoid administration. Clinical and hormonal findings.
Topics: Aged; Aminoglutethimide; Breast Neoplasms; Female; Glucocorticoids; Hormones; Humans; Menopause; Mid | 1992 |
[Results of hormone therapy with aminoglutethimide (Rodazol) in postmenopausal metastatic breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Aminoglutethimide; Breast Neoplasms; Female; Follow-Up Studies; Huma | 1991 |
[Growth inhibition of MCF-7 human breast cancer cells by aromatase inhibitors].
Topics: Aminoglutethimide; Aromatase Inhibitors; Breast Neoplasms; Cyproterone; Cyproterone Acetate; Female; | 1991 |
Endocrine and clinical aspects of new compounds for treatment of hormone-related cancer in gynecology.
Topics: Aminoglutethimide; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Buserelin; Female; Goser | 1990 |
[Experimental multihormone therapy on human breast carcinomas grown in nude mice].
Topics: Aminoglutethimide; Animals; Drug Therapy, Combination; Estrogens; Female; Mammary Neoplasms, Experim | 1989 |
[The effect of aminoglutethimide on steroid synthesis of the adrenal gland and its use in prostate cancer].
Topics: Adrenal Cortex; Aged; Aged, 80 and over; Aminoglutethimide; Androgens; Combined Modality Therapy; Hu | 1989 |
[Changes in serum lipoproteins under hormonal therapy of breast carcinoma and other endocrine-dependent tumors].
Topics: Aminoglutethimide; Breast Neoplasms; Cholesterol; Cortisone; Drug Therapy, Combination; Female; Huma | 1985 |
[Therapeutic results obtained with aminoglutethimide in advanced-stage breast cancer. Factors predictive of a response].
Topics: Adult; Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Es | 1986 |
Clinical studies with aminoglutethimide in advanced breast carcinoma.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Evaluation | 1986 |
[Aminoglutethimide in the treatment of metastasizing breast carcinoma in old age].
Topics: Aged; Aged, 80 and over; Aminoglutethimide; Breast Neoplasms; Female; Humans; Menopause; Middle Aged | 1987 |
Aromatase inhibitors and the treatment of breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Androstenedione; Animals; Aromatase Inhibitors; Breast Neoplasms; Es | 1986 |